EXCLUSIVE: Alzamend Neuro Submits IND For Phase IIA Trial Of Next-Gen Lithium Candidate In Major Depressive Disorder [Yahoo! Finance]
Alzamend Neuro, Inc. (ALZN)
Company Research
Source: Yahoo! Finance
Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for treating Alzheimer's, BD, MDD, and PTSD. Lithium, although not FDA-approved for MDD augmentation, has been used off-label for years, the company said. It's the FDA's first-approved mood stabilizer and remains a first-line treatment for BD, but it is underutilized, which may be due to required therapeutic drug monitoring (TDM). AL001 is a novel lithium-delivery system that can potentially deliver the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium. Following the FDA's ‘study may proceed' communication, Alzamend aims to start a Phase IIA study to characterize AL001 improvements of lithium levels in the brain compared to a marketed lithium salt in MDD patients. Alzamend says this IND submission represents a significant milestone in advancing the company's proprietary pipeline. “Being able to develop a n
Show less
Read more
Impact Snapshot
Event Time:
ALZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALZN alerts
High impacting Alzamend Neuro, Inc. news events
Weekly update
A roundup of the hottest topics
ALZN
News
- Alzamend Neuro (NASDAQ:ALZN) had its price target lowered by analysts at Ascendiant Capital Markets from $42.00 to $28.00. They now have a "buy" rating on the stock.MarketBeat
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital [Yahoo! Finance]Yahoo! Finance
- Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General HospitalPR Newswire
- Alzamend Neuro (NASDAQ:ALZN) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
ALZN
Analyst Actions
- 12/22/25 - Ascendiant Capital
ALZN
Sec Filings
- 12/23/25 - Form 4
- 12/9/25 - Form 10-Q
- 11/18/25 - Form 8-K
- ALZN's page on the SEC website